Insights
Search Results
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
3.13.26
Firm Advises BlackLine on Agreement with Engaged Capital
On March 10, 2026, BlackLine announced that it entered into a cooperation agreement with Engaged Capital. Under this agreement, BlackLine appointed Storm Duncan and Megan Prichard to its board of directors, and Engaged Capital agreed to various restrictions on its activities at BlackLine. Wilson Sonsini Goodrich & Rosati advised BlackLine on the cooperation agreement.
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
1.08.26
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly
On January 7, 2026, Eli Lilly and Company announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases. Under the terms of the agreement, Lilly will acquire all the outstanding shares of Ventyx in an all-cash transaction, valuing at approximately $1.2 billion. Wilson Sonsini is advising Ventyx on the transaction.
Client Highlights
12.02.25
Wilson Sonsini Advises Marvell on Acquisition of Celestial AI
On December 2, 2025, Marvell Technology, a leader in data infrastructure semiconductor solutions, announced it has entered into a definitive agreement to acquire Celestial AI, a pioneer of a disruptive Photonic Fabric technology platform purpose-built for scale-up optical interconnect. Wilson Sonsini Goodrich & Rosati is advising Marvell on the transaction.
Client Highlights
10.17.25
Wilson Sonsini Advises Omeros on Asset Purchase and License Agreement with Novo Nordisk
On October 15, 2025, Novo Nordisk and Omeros Corporation announced that they have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (OMS906) in clinical development for rare blood and kidney disorders. Wilson Sonsini Goodrich & Rosati advised Omeros on the transaction.
Client Highlights
10.13.25
Wilson Sonsini Advises Fivetran on Merger with dbt Labs
On October 13, 2025, Fivetran, a global leader in automated data movement, announced that it signed a definitive agreement to merge with dbt Labs, a pioneer of modern data transformation, in an all-stock deal. The combined company will be approaching $600 million in annual recurring revenue. The transaction marks significant consolidation in the data tooling market as enterprises race to adapt infrastructure for artificial intelligence applications. Wilson Sonsini Goodrich & Rosati advised Fivetran on the transaction.
Client Highlights
6.27.25
Wilson Sonsini Advises Xero on Acquisition of Melio for up to $3 Billion
On June 24, 2025, New Zealand-based Xero Limited, a global small business platform that helps customers supercharge their business by bringing together the most important small business tools, announced it has entered into an agreement to acquire U.S.-based Melio Limited, a leading SMB bill pay platform that seamlessly integrates accounting and payments, and its associated entities (collectively Melio). The acquisition is expected to be funded through a mix of cash and equity, with an upfront consideration of $2.5 billion in cash and equity consideration and up to $500 million in contingent consideration, deferrals and rollovers payable to Melio employees. Wilson Sonsini Goodrich & Rosati is serving as lead counsel to Xero on the acquisition.
Client Highlights
6.20.25
Wilson Sonsini Advises Couchbase on $1.5 Billion Acquisition by Haveli Investments
Couchbase, the developer data platform for critical applications in AI, announced that it has entered into a definitive agreement to be acquired by Haveli Investments, a technology-focused investment firm, in an all-cash transaction valued at approximately $1.5 billion. Wilson Sonsini Goodrich & Rosati is advising Couchbase on the transaction.
News Articles
6.17.25
M&A Advisor Recognizes Ross Tanaka as a 2025 "Emerging Leader"
On June 3, 2025, Wilson Sonsini M&A partner Ross Tanaka was honored among this year's recipients for the 16th annual "Emerging Leaders Awards" by M&A Advisor, a globally renowned organization for recognizing and showcasing top M&A, financing, and turnaround transactions and professionals. The honorees are rising stars shaping the future of mergers and acquisitions, restructuring, and corporate finance. The winners will be recognized at a formal awards gala in New York City in September.